icon-    folder.gif   Conference Reports for NATAP  
 
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
 
 
 
Maviret /G-P in HIV+ Coinfected / ART DDIs
 
 
  IAS: Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17)
 
IAS: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17)
 
Additional slides

0912171

0912172